Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
12 Dec 2016 PI3K Inhibitor Buparlisib in Combination with Fulvestrant Prolongs PFS Compared to Placebo Plus Fulvestrant Translational research - Anticancer agents & Biologic therapy
09 Dec 2016 CAR T-Cell Immunotherapy Induces Complete Remissions in Patients with Refractory DLBCL Haematologic malignancies - Cancer Immunology and Immunotherapy
07 Dec 2016 Durvalumab in Heavily Pretreated EGFR/ALK Wildtype Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
07 Dec 2016 ESMO Asia 2016 Press Release: Supportive Care for Cancer Patients Remains Inadequate Palliative and supportive care
07 Dec 2016 ESMO Asia 2016 Press Release: Patients Wait Four Months Before Seeking Cancer Diagnosis
06 Dec 2016 PFS Significantly Longer With Osimertinib Than With Platinum-Pemetrexed in EGFR T790M-Positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
05 Dec 2016 Suicide in Survivors of Cancer in Childhood, Adolescence and Young Adulthood Cancer in Special Situations
25 Nov 2016 ESC Position Paper on Anticancer Treatments and Cardiovascular Toxicity Palliative and supportive care
24 Nov 2016 NICE Issues Evidence Based Recommendations on Nivolumab for Previously Treated Advanced RCC Genitourinary cancers - Cancer Immunology and Immunotherapy
23 Nov 2016 FDA Approves Daratumumab in Combination with Lenalidomide and Dexamethasone or Bortezomib and Dexamethasone for Multiple Myeloma Treatment Haematologic malignancies - Anticancer agents & Biologic therapy
21 Nov 2016 EMA Revises the Guideline on First-in-Human Clinical Trials Bioethics, legal and economic issues
16 Nov 2016 Direct Small-Molecule Inhibitors of KRAS Translational research
15 Nov 2016 EMA Recommends Extension of Therapeutic Indications for Ofatumumab Haematologic malignancies - Anticancer agents & Biologic therapy
14 Nov 2016 EMA Recommends Extension of Therapeutic Indications for Vandetanib Endocrine cancers - Anticancer agents & Biologic therapy
11 Nov 2016 FDA Approves Nivolumab for SCCHN Head and neck cancers - Cancer Immunology and Immunotherapy